What is the use of N-acetyl L leucine?
•
4 min read
In September 2024, the U.S. Food and Drug Administration (FDA) approved N-acetyl L leucine (NALL) for the treatment of neurological manifestations associated with Niemann-Pick disease type C (NPC). The use of N-acetyl L leucine, also known as levacetylleucine, represents a significant development for patients with this rare and progressive neurodegenerative disorder. Beyond NPC, the compound has shown promise in treating other conditions characterized by balance and coordination problems.
